Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

dequate response in MDD - Today Shire announced positive results from a Phase 2 clinical trial of VYVANSE as adjunctive therapy for patients who have had an inadequate response in their treatment of MDD. Given the encouraging results and the promise to treat a large unmet medical need, Shire will initiate Phase 3 trials of VYVANSE in patients with MDD mid 2011, following health authority meetings to establish the development program parameters. Phase 2 clinical trials in additional non-ADHD indications (treatment of negative symptoms and cognitive impairment in schizophrenia and for the treatment of cognitive impairment in depression) remain ongoing. SPD535 for the treatment of arteriovenous grafts in hemodialysis patients - SPD535 is a novel platelet reducing agent. Phase 1 development was initiated in the third quarter of 2009 and is ongoing. Data from Phase 1 clinical trials demonstrating positive proof-of-principle have been completed. The initial Phase 2 proof-of-concept program will target prevention of thrombotic complications associated with arteriovenous grafts in hemodialysis patients. Additional Phase 2 proof-of-concept clinical trials will also be initiated to assess opportunities in other indications. INTUNIV for ADHD in the EU - A clinical program to support the filing of a Marketing Authorization Approval for INTUNIV for the treatment of ADHD in children aged 6 to 17 in the EU has been initiated. Shire anticipates submission of the regulatory filing for INTUNIV in Europe will occur in 2013. OTHER THIRD QUARTER AND RECENT DEVELOPMENTS Acquisition of Movetis - On September 6, 2010 Shire launched a voluntary public takeover offer for all the shares in Movetis, a Belgium-based speciality GI company, for a fully diluted equity purchase price of EUR428 million (or EUR19 per share) in cash, equivalent to $592 million at closing of the transaction. - On October 12, 2010 the Company's wholly owned subsidiary, Shire Holdings Luxembourg S.a.r.l. acquired 99.21%
'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Frederick, MD (PRWEB) February 26, 2015 ... solutions provider, released FreezerPro® version 6.2 – the latest ... The FreezerPro® reputation is that of a quick and ... related work. With the latest version, RURO engineering has ... on import to move large amounts of sample records. ...
(Date:2/26/2015)... Feb. 26, 2015  Dyadic International, Inc. ("Dyadic") ... and proprietary technologies are used to develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... results for year ending December 31, 2014 after ... will host a conference call that day at ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015 ... Gold Partner status in Oracle PartnerNetwork. In attaining Gold ... its commitment to establish Oracle-related knowledge in delivering Ceres, ... challenges of joint customers. Originally developed for ... to rapidly zoom in and out of massive amounts ...
(Date:2/26/2015)... Feb. 26, 2015  Epic Sciences announced today that ... present at the 35th Annual Cowen and Company Health ... the MIT Room, 3rd Floor. The conference will be ... Mass. Epic is developing diagnostic tests of ... and proteomic changes that occur during the course of ...
Breaking Biology Technology:RURO Releases FreezerPro® version 6.2 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2
... demonstrates mortality reduction in endotoxemic patients through use ... of combined diagnostic and ... Diagnostics Inc.,(TSX:SDI) today announced that new findings were presented ... use of,Spectral,s EAA(TM) Endotoxin Activity Assay, the only FDA ...
... for prevention of insulin-induced hypoglycemia in ... ... March 18 DiObex and,Camurus announced today that they have signed ... drug delivery,technology, FluidCrystal(R). The development candidate is an extended,release formulation of ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTAX) management will present at ... Pacific Time,(PT) in the Bay Auditorium of the Bell Harbor Conference Center., ... the presentation. The webcast can be accessed at, http://www.celltherapeutics.com ., ... WBBA Invest Northwest Conference ...
Cached Biology Technology:Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine 2DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology 2
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... --NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces the launch ... part of its 2015 marketing and branding initiatives for ... consumer website for Wocketwallet.com earlier this month. ... "Our new corporate website naturally showcases our premiere consumer ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... that ever walked the earthIndricotherium transouralicum, a hornless ... stood about eighteen feet high at the shoulderlived ... largest mammal that ever walked the earth Indricotherium ... approximately seventeen tons and stood about eighteen feet ...
... and other pathogens result in global crop losses of over ... Institution,s Department of Plant Biology developed a novel trick for ... organism. They discovered a novel family of pores that transport ... pores to access the plant sugar for food. The first ...
... , In the scorching summer heat of the Chihuahuan ... 97F (36C) while at the surface of the soil ... extreme temperatures, plants must utilize creative methods to not ... lethal conditions. This new work by Dr. Gretchen ...
Cached Biology News:Giants among us: Paper explores evolution of the world’s largest mammals 2Giants among us: Paper explores evolution of the world’s largest mammals 3How pathogens hijack host plants 2How pathogens hijack host plants 3Can cacti 'escape' underground in high temperatures? 2
... proto-oncogene was first identified as the cellular homolog ... B and Jun D have been shown to ... regions, which are involved in dimerization and DNA ... in transcriptional activation, diverge. Antigen: ...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
... eBioscience Intracellular (IC) Fixation Buffer, ... Buffer (Cat. No. 00-8333), can be ... prior to performing intracellular staining of ... antigens. These solutions have been specially ...
... III is intented for ... PBMCs (or lysed whole ... intracellular kinases and appropriate ... Applications: Intracellular Staining (Flow) ...
Biology Products: